(HealthDay)—Long-term cardiomyopathy risk varies by chemotherapy agent for childhood cancer survivors, with a decreased risk for daunorubicin versus doxorubicin, according to a study recently published in JAMA Oncology.
* This article was originally published here
This Blog Is Powered By Life Technology™. Visit Life Technology™ At www.lifetechnology.com Subscribe To This Blog Via Feedburner / Atom 1.0 / RSS 2.0.